Home>Topics>Stocks>AstraZeneca PLC ADR

AstraZeneca PLC ADR AZN

  1. All
  2. Commentary
  3. Video Reports
  4. Headlines
    1. Pfizer Posts Strong 4Q, but Lack of Strong Growth Outlook Is Likely to Drive Acquisitions

      Commentary

      Tue, 27 Jan 2015

      acquiring smaller firms with innovative drugs in unmet medical areas of need. Further, Pfizer's willingness to walk away from the AstraZeneca acquisition increases our confidence in Pfizer's financial discipline when acquiring assets.

    2. Pfizer May Go Shopping for Growth

      Headlines

      Tue, 27 Jan 2015

      firms with innovative drugs in unmet medical areas of need. Further, Pfizer's willingness to walk away from the AstraZeneca AZN acquisition increases our confidence in Pfizer's financial discipline when acquiring assets. Morningstar Premium

    3. UPDATE 1-FDA approves Teva's generic version of AstraZeneca's Nexium

      Headlines

      Mon, 26 Jan 2015

      Jan 26 (Reuters) - The U.S. Food and Drug Administration said it approved Teva Pharmaceutical Industries Ltd's generic version of AstraZeneca Plc's blockbuster heartburn drug Nexium, the agency's first such approval for the drug.

    4. FDA approves Teva's generic version of AstraZeneca's Nexium

      Headlines

      Mon, 26 Jan 2015

      Jan 26 (Reuters) - The U.S. Food and Drug Administration said it approved Teva Pharmaceutical Industries Ltd's generic version of AstraZeneca Plc's Nexium to treat acid reflux, the agency's first...

    5. Salivary Gland Cancer - Pipeline Review, H2 2014

      Commentary

      Wed, 21 Jan 2015

      Gland Cancer - Companies Involved in Therapeutics Development AstraZeneca PLC Bayer AG Incuron, LLC Novartis AG Otsuka Holdings Co ..... Institutes, H2 2014 Salivary Gland Cancer - Pipeline by AstraZeneca PLC, H2 2014 Salivary Gland Cancer - Pipeline by Bayer AG

    6. UPDATE 2- AstraZeneca heart drug boosted by major clinical trial success

      Headlines

      Wed, 14 Jan 2015

      * AstraZeneca shares up 1.5 percent (Adds executive interview, consensus sales forecast, more reaction)

    7. BRIEF- AstraZeneca says heart drug study meets primary endpoint

      Headlines

      Wed, 14 Jan 2015

      * PEGASUS-TIMI 54 study, a large scale outcomes trial involving over 21,000 patients, successfully met its primary efficacy endpoint

    8. Leader in Genomic Sequencing Illuminates the Way

      Headlines

      Wed, 14 Jan 2015

      machines like NextSeq following shortly. Illumina has also announced gene panel test partnerships with Johnson & Johnson, AstraZeneca , Sanofi, and Amgen (for Vectibix). Management Faces a Tall Order in Sustaining Illumina's Leadership We rate Illumina

    9. AstraZeneca loses German court appeal over Seroquel XR drug patent

      Headlines

      Tue, 13 Jan 2015

      KARLSRUHE, Germany, Jan 13 (Reuters) - Britain's AstraZeneca Plc on Tuesday lost an appeal in Germany's Federal Court against generic drugmakers selling cheap copies of its anti-psychotic drug Seroquel XR.

    10. AstraZeneca in cancer viruses deal with Omnis Pharmaceuticals

      Headlines

      Mon, 12 Jan 2015

      LONDON, Jan 12 (Reuters) - AstraZeneca said on Monday its MedImmune biotech unit had struck a deal with unlisted U.S. company Omnis Pharmaceuticals on the development of cancer-fighting oncolytic viruses.

    « Prev12345Next »
    Content Partners